Korean J Urol Oncol.
2022 May;20(2):82-91. 10.22465/kjuo.2022.20.2.82.
The Present and Future of Intravesical Therapy in Bladder Cancer
- Affiliations
-
- 1College of Medicine, Chung-Ang University, Seoul, Korea
- 2Department of Urology, Chung-Ang University Hospital, Seoul, Korea
- 3Department of Urology, Hanil General Hospital, Seoul, Korea
- KMID: 2530294
- DOI: http://doi.org/10.22465/kjuo.2022.20.2.82
Abstract
- Intravesical therapy is the gold standard in the treatment of nonmuscle invasive bladder cancer (NMIBC). Despite the efficacy of intravesical therapies, the best treatment options are not determined yet. Development in research of bladder cancer shows several new intravesical drugs and its delivery systems. Additionally, the novel knowledge of bladder cancer immune reaction improves and provides ambitious treatment strategies. The future of NMIBC therapy will be changed by the development of immunotherapy and new technologies for device-assisted treatment. This review focuses on recent advances in the intravesical therapy of NMIBC, viral gene therapy, new technology of intravesical chemotherapy, and drug delivery system.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Intravesical Therapy for Superficial Bladder Cancer: Advances and Future
- Nanomedicines for Therapy of Bladder Cancer
- Anticancer Activity of Intravesical Glyceryl Monooleate (GMO)-Paclitaxel Therapy in Murine Superficial Transitional Cell Carcinoma Model Induced by BBN
- A Clinical Observation of the Intravesical Thiotepa in Bladder Cancer
- Prophylactic effect of intravesical BCG therapy in superficial bladder cancer
